Orsolya Berezvai's research while affiliated with Pázmány Péter Catholic University and other places

What is this page?


This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.

It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.

If you're a ResearchGate member, you can follow this page to keep up with this author's work.

If you are this author, and you don't want us to display this page anymore, please let us know.

Publications (1)


Figure 2. Structure of the "skin-on-a chip" microfuidic diffusion cell. PDMS: polydimethyl-siloxane; PMMA: polymethyl-metacrylate.
Figure 3. Two simultaneous "skin-on-a chip" experimental setups. The system consists of a programmable syringe pump and a flow-through dynamic microfluidic device. In this photo, the penetration of an active ingredient from a cream formulation across a rat skin preparation was being tested. The collection vials were placed below the devices in the sampling bench.
Figure 4. Concentration-time profiles determined in Franz diffusion cells in freshly prepared (A,B,E,F) and frozen (C,D) rat skin samples. Erythromycin (ERY) absorption was measured (A-D) in young (A,C) and aged (B,D) skin preparations. Quinidine (QND) absorption was measured (E,F) in young (E) and aged (F) skins. Both ERY and QND were applied as a 2% cream. The black lines show the groups where the skins were pretreated with DMSO followed by ERY or QND treatment. The red lines show the groups where the skins were pretreated with PSC-833 containing DMSO followed by ERY or QND treatment. n = 3. The statistical analysis of generated AUC and Cmax data is presented in Figures 5 and 6.
Figure 6. Multiple comparison of means of area under the concentration-time curves (AUC-s) of P-gp substrate penetration across the dermal barrier by Tukey test. (Panel A) Aged and young, frozen rat skin samples were compared for erythromycin (ERY) penetration in the presence or absence of PSC-833 pretreatment. (Panel B) Aged and young, freshly prepared rat skin samples were compared for erythromycin (ERY) penetration in the presence or absence of PSC-833 pretreatment. (Panel C) Aged and young, freshly prepared rat skin samples were compared for quinidine (QND) penetration in the presence or absence of PSC-833 pretreatment.
Verification of P-Glycoprotein Function at the Dermal Barrier in Diffusion Cells and Dynamic “Skin-On-A-Chip” Microfluidic Device
  • Article
  • Full-text available

August 2020

·

407 Reads

·

23 Citations

Pharmaceutics

·

·

Orsolya Berezvai

·

[...]

·

The efficacy of transdermal absorption of drugs and the irritation or corrosion potential of topically applied formulations are important areas of investigation in pharmaceutical, military and cosmetic research. The aim of the present experiments is to test the role of P-glycoprotein in dermal drug delivery in various ex vivo and in vitro platforms, including a novel microchip technology developed by Pázmány Péter Catholic University. A further question is whether the freezing of excised skin and age have any influence on P-glycoprotein-mediated dermal drug absorption. Two P-glycoprotein substrate model drugs (quinidine and erythromycin) were investigated via topical administration in diffusion cells, a skin-on-a-chip device and transdermal microdialysis in rat skin. The transdermal absorption of both model drugs was reduced by P-glycoprotein inhibition, and both aging and freezing increased the permeability of the tissues. Based on our findings, it is concluded that the process of freezing leads to reduced function of efflux transporters, and increases the porosity of skin. P-glycoprotein has an absorptive orientation in the skin, and topical inhibitors can modify its action. The defensive role of the skin seems to be diminished in aged individuals, partly due to reduced thickness of the dermis. The novel microfluidic microchip seems to be an appropriate tool to investigate dermal drug delivery.

Download
Share

Citations (1)


... The capillaries present the highest cross-sectional surface for fluid perfusion in the body. The currently available organ-on-a-chip or skin-on-a-chip systems apply different perfusion flow rates depending on the microchannel design and the placement and integration of cells or ex vivo tissues in the devices [5][6][7][8][9]. To achieve physiologically relevant conditions, the shear stress on the channel wall and cells and the tissue preparations should be considered. ...

Reference:

Fluid Dynamics Optimization of Microfluidic Diffusion Systems for Assessment of Transdermal Drug Delivery: An Experimental and Simulation Study
Verification of P-Glycoprotein Function at the Dermal Barrier in Diffusion Cells and Dynamic “Skin-On-A-Chip” Microfluidic Device

Pharmaceutics